Pharma BD Deal Intelligence
Novo Nordisk and Valo Health entered a discovery/development collaboration on Sept 25, 2023, leveraging Valo's Opal Computational Platform and proprietary human dataset to identify novel cardiovascular/cardiometabolic targets. Original terms: $60M in upfront/near-term payments and eligibility for up to $2.7B across up to 11 programs in milestones, plus R&D funding and royalties. On Jan 8, 2025 the partners EXPANDED the alliance: scope broadened to obesity and type 2 diabetes in addition to cardiovascular disease, the program count rose to up to 20 (9 new programs), and Valo became eligible for ~$4.6B in milestones with up to $190M in near-term payments (upfront plus an equity investment by Novo Nordisk and a potential near-term milestone), again with R&D funding and tiered royalties. Novo's CSO Marcus Schindler cited first-year progress and the addition of several novel cardiometabolic targets as the rationale for the expansion. Note: Valo's separate wholly-owned ROCK inhibitor OPL-0401 failed its Phase 2 diabetic-retinopathy endpoint and was suspended; that asset is outside the Novo collaboration and does not bear on this deal's programs.